Regeneron Pharmaceuticals, Inc.
Biopharmaceutical company Regeneron Pharmaceuticals, Inc. and global life science business Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases.
Two separate Phase 2 clinical studies are reportedly evaluating the combination therapy as a co-formulated single intravitreal injection in patients with wet age-related macular degeneration (AMD) or diabetic macular edema. Preclinical data demonstrates that angiopoietins act together with the VEGF family to promote the formation and maturation of blood and lymphatic vessels in the eye. Ang2 and VEGF together therefore have the potential to influence the pathological development of new blood vessels and the permeability of blood vessel walls in certain diseases of the eye.
Regeneron and Bayer currently collaborate on the global development and commercialization of EYLEA® (aflibercept) Injection and on the global development of REGN2176-3, the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) antibody rinucumab co-formulated in a single intravitreal injection with aflibercept, which is currently in Phase 2 clinical trials for patients with wet age-related macular degeneration.
Click here to read the full press release.